Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LGK974 · 1 trial · 8 indications
DLT is defined as an adverse event or abnormal laboratory value that is assessed by the investigator as unrelated to disease, disease progression, intercurrent illness, or concomitant medications and that meets the criteria defined in the study protocol. The objective was to determine the Maximum Tolerated Dose (MTD) or Recommended Dose for Expansion (RDE) of LGK974 as a single agent and in combination with PDR001 when administered orally to adult patients with malignancies dependent on Wnt ligands.
| Arm | Type | Description |
|---|---|---|
| LGK974 | EXPERIMENTAL | LGK974 |
| LGK974 in combination with PDR001 | EXPERIMENTAL | LGK in combination with PDR001 |
| Name | Type | Description |
|---|---|---|
| LGK974 | DRUG | - |
| PDR001 | BIOLOGICAL | - |
Inclusion Criteria: Diagnosis of locally advanced or metastatic cancer that has progressed despite standard therapy or for which no effective standard therapy exists and histological confirmation of one of the following diseases indicated below: Single Agent Dose escalation part:documented B-RAF m...
Top 20 of 68 competitors
LGK974 is an investigational small molecule being studied for the treatment of pancreatic cancer. It is also being evaluated in other Wnt ligand-dependent malignancies, including BRAF mutant colorectal cancer, melanoma, triple negative breast cancer, and several squamous cell cancers. It is currently in Phase 1 clinical development.
LGK974 targets the Wnt signaling pathway by inhibiting Wnt ligand production. This pathway is implicated in the growth and survival of certain cancers, including pancreatic cancer. By blocking Wnt ligands, LGK974 aims to disrupt tumor cell proliferation in malignancies that depend on this signaling pathway.
LGK974 is being developed by Novartis AG, a multinational pharmaceutical company headquartered in Basel, Switzerland. Novartis is listed on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and efficacy of LGK974 in patients with Wnt ligand-dependent cancers.
LGK974 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is no longer in active clinical trials. Its safety and efficacy have not been established.
LGK974 has been studied in one clinical trial, registered as NCT01351103. This Phase 1 study, titled 'A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,' was completed and enrolled 185 participants. The trial was conducted in the United States, Canada, France, Germany, Italy, Netherlands, and Spain.
LGK974 is the primary name for this investigational compound. No alternative names have been disclosed in the available clinical trial information. It is a small molecule developed by Novartis, and it is distinct from other Wnt pathway inhibitors currently in development.